Client News

Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206

Qanatpharma, Zuse Institute Berlin, Enamine, and Proteros biostructures Announce Generative-AI Driven Lead Discovery Collaboration

Formycon AG: Bio Usawa Becomes Partner for the Commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa

AFTER-BIOCHEM: A European Flagship Project Comes to a Close, Paving the Way for Sustainable Industrial Green Chemistry

Mallia Appoints Jens Holstein, Dr. Alexandra Ogilvie, and Dr. Ulrich Dauer to its Advisory Board

AFTER-BIOCHEM: A European Flagship Project Comes to a Close, Paving the Way for Sustainable Industrial GREEN Chemistry

Gemeinsam für eine bessere Zukunft: Ipsen Pharma GmbH engagiert sich am Community Day 2025 für Menschen und Umwelt

ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility

invIOs Reports Promising Phase 1b Results for Cell Therapy APN401 in Advanced Solid Tumors

Formycon Increases Bond Volume Following Oversubscription – Bond 2025/2029 with a Volume of EUR 70 Million Successfully and Entirely Placed